JP Morgan initiated coverage on Dr. Reddy's
$RDY
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan initiated coverage of Dr. Reddy's with a rating of Underweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/23/2026 | Neutral → Sell | Goldman | |
| 6/5/2025 | $16.89 | Hold → Buy | HSBC Securities |
| 12/19/2024 | Buy → Neutral | Nomura | |
| 1/11/2024 | Buy → Underperform | Jefferies | |
| 8/29/2023 | Buy → Hold | HSBC Securities | |
| 5/18/2023 | Outperform → Mkt Perform | Bernstein | |
| 3/17/2023 | Neutral → Buy | BofA Securities | |
| 1/30/2023 | Underweight | JP Morgan |
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
6-K - DR REDDYS LABORATORIES LTD (0001135951) (Filer)
Submission status for DR. REDDY'S LABORATORIES LIMITED's drug PALBOCICLIB (ORIG-1) with active ingredient PALBOCICLIB has changed to 'Tentative Approval' on 05/15/2026. Application Category: ANDA, Application Number: 220444, Application Classification:
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
3 - DR REDDYS LABORATORIES LTD (0001135951) (Issuer)
Goldman downgraded Dr. Reddy's from Neutral to Sell
HSBC Securities upgraded Dr. Reddy's from Hold to Buy and set a new price target of $16.90
Nomura downgraded Dr. Reddy's from Buy to Neutral
NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 29, 2026 /CNW/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on May 29thThe S&P 500 will look to extend its record run as investors digest new developments in the Middle East.Shares of Global X NYSE 100 ETF Component Dell Technologies (NYSE:DELL) popped in extended trading after reporting Q1 earnings Thursday afternoon.Asana (NYSE:ASAN) CEO Dan Rogers will join Taking Stock to discuss how
The launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada Canada is the first G7 country to grant market authorization for generic Semaglutide Injection Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), a global pharmaceutical company, today announced the launch of its generic Semaglutide Injection in Canada. Dr. Reddy's is among the first companies to intro
Dr. Reddy's becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted to Dr. Reddy's ahead of Health Canada's review target date Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), a global pharmaceutical company, today announced that it has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. Dr. Reddy's becomes the first company to receive the market authorization for generic Semaglutide Injection* in Canada, ahead of Health Canada's review target date. The
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13D/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SC 13G/A - DR REDDYS LABORATORIES LTD (0001135951) (Subject)
SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as ", Dr. Reddy', s", ) for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclusive rights to commercialize both subcutaneous and intravenous formulation of HLX15 in a total of 43 countries and regions, comprising 42 European countries and
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan Kalawadia as Chief Executive Officer, North America, and member of the Management Council. As part of the Dr. Reddy's senior leadership team, he will be responsible for the company's North America business and will be based out of the Princeton, New Jersey, U.S. office. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528120424/en/Milan Kalawadia (Photo: Business Wire) "I am excited to start this next chapter in my journey at Dr
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q1 FY26 Revenues ₹ 85,452 Mn [Up: 11% YoY; Flat QoQ] Gross Margin 56.9% [Q1FY25: 60.4%; Q4FY25: 55.6%] SG&A Expenses ₹ 25,647 Mn [Up: 13% YoY; 7% QoQ] R&D Expenses ₹ 6,244 Mn [7.3% of Revenues] EBITDA ₹ 22,784 Mn [26.7% of Revenues] Profit before
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q4FY25 FY25 Revenues ₹ 85,060 Mn ₹ 325,535 Mn [Up: 20% YoY^; 2% QoQ] [Up: 17% YoY^] Gross Margin 55.6% 58.5% [Q4FY24: 58.6%; Q3FY25: 58.7%] [FY24: 58.6%] SG&A Expenses ₹ 24,055 Mn ₹ 93,870 Mn [Up: 17% YoY; Flat QoQ] [Up: 22% YoY] R&D Expens
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned in this release is based on consolidated financial statements under International Financial Reporting Standards (IFRS). Q3FY25 9MFY25 Revenues ₹ 83,586 Mn ₹ 240,475 Mn [Up: 16% YoY^; 4% QoQ] [Up: 15% YoY^] Gross Margin 58.7% 59.5% [Q3FY24: 58.5%; Q2FY25: 59.6%] [9MFY24: 58.6%] SG&A Expenses ₹ 24,117 Mn ₹ 69,815 Mn [Up: 19% YoY; 5% QoQ] [Up: 23% YoY] R&D Expenses ₹ 6,658 Mn ₹ 20,122 Mn [8.0% o